Results 241 to 250 of about 13,689,528 (374)
TRPM8 levels determine tumor vulnerability to channel agonists
TRPM8 is a Ca2+ permissive channel. Regardless of the amount of its transcript, high levels of TRPM8 protein mark different tumors, including prostate, breast, colorectal, and lung carcinomas. Targeting TRPM8 with channel agonists stimulates inward calcium currents followed by emptying of cytosolic Ca2+ stores in cancer cells.
Alessandro Alaimo+18 more
wiley +1 more source
Analogs of the Prime Number Problem in a Shot Noise Suppression of the Soft-Reset Process. [PDF]
Hirose Y.
europepmc +1 more source
On the zero points of a bounded analytic function [PDF]
Masatsugu Tsuji
openalex +1 more source
The pan‐HDAC inhibitor belinostat increases the expression of the pro‐apoptotic proteins Bim, Puma, and Noxa and induces apoptosis in ovarian cancer cell lines and patient‐derived tumor organoids when used at high concentrations. Moreover, inhibiting the anti‐apoptotic proteins Bcl‐xL or Mcl‐1 sensitizes these preclinical models to the cytotoxic effect
Cécilia Thomine+10 more
wiley +1 more source
On a Countable Sequence of Homoclinic Orbits Arising Near a Saddle-Center Point. [PDF]
Baldomá I, Guardia M, Pelinovsky DE.
europepmc +1 more source
Maximum Principle for Analytic Functions on Open Riemann Surfaces. [PDF]
Yukio Kusunoki
openalex +1 more source
The COMBAT classification system, developed through multi‐omics integration, stratifies adult patients with B‐cell acute lymphoblastic leukemia(B‐ALL) into three molecular subtypes with distinct surface antigen patterns, immune landscape, methylation patterns, biological pathways and prognosis.
Yang Song+11 more
wiley +1 more source
Cut from the same cloth: neurobiological continuity between childhood and adult ADHD. [PDF]
Shaw P.
europepmc +1 more source
On mixed boundary value problems for functions analytic in a simply-connected domain [PDF]
Yûsaku Komatu
openalex +1 more source
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton+17 more
wiley +1 more source